Molecular Management of High-Grade Serous Ovarian Carcinoma
Open Access
- 9 November 2022
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (22) , 13777
Abstract
High-grade serous ovarian carcinoma (HGSOC) represents the most common form of epithelial ovarian carcinoma. The absence of specific symptoms leads to late-stage diagnosis, making HGSOC one of the gynecological cancers with the worst prognosis. The cellular origin of HGSOC and the role of reproductive hormones, genetic traits (such as alterations in P53 and DNA-repair mechanisms), chromosomal instability, or dysregulation of crucial signaling pathways have been considered when evaluating prognosis and response to therapy in HGSOC patients. However, the detection of HGSOC is still based on traditional methods such as carbohydrate antigen 125 (CA125) detection and ultrasound, and the combined use of these methods has yet to support significant reductions in overall mortality rates. The current paradigm for HGSOC management has moved towards early diagnosis via the non-invasive detection of molecular markers through liquid biopsies. This review presents an integrated view of the relevant cellular and molecular aspects involved in the etiopathogenesis of HGSOC and brings together studies that consider new horizons for the possible early detection of this gynecological cancer.Keywords
Funding Information
- Miguel Servet Spanish Program (CP19/00162)
- Carlos III Institute, Spain (PI20/00942)
- Ph.D. Training Grant for Valencian Entities (ACIF/2021/348)
This publication has 312 references indexed in Scilit:
- A 2‐stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early‐stage incident cancers and demonstrates high positive predictive valueCancer, 2013
- Ovarian Cancer Screening: Development of the Risk of Ovarian Cancer Algorithm (ROCA) and ROCA Screening TrialsInternational Journal of Gynecological Cancer, 2012
- Ovarian Cancer is an Imported Disease: Fact or Fiction?Current Obstetrics and Gynecology Reports, 2012
- Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencingProceedings of the National Academy of Sciences, 2011
- Unraveling the mechanism of BRCA2 in homologous recombinationNature Structural & Molecular Biology, 2011
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case–Control StudyJNCI: Journal of the National Cancer Institute, 2010
- A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic massGynecologic Oncology, 2009
- RETRACTED: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancerGynecologic Oncology, 2008
- Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancerThe Journal of Pathology, 2001